aromatic amino acid
branched-chain amino acid
polymerase chain reaction
- • The amino acid (AA) transporter TAT1 (Slc16A10) mediates facilitated diffusion of aromatic AAs (AAAs) across membranes.
- • TAT1 null mice lack liver control of AAAs and display altered epithelial AA transport.
- • The data support the hypothesis that equilibrative transport of essential AAs by TAT1 is crucial for body AA homeostasis control.
Abstract The uniporter TAT1 (Slc16a10) mediates the facilitated diffusion of aromatic amino acids (AAAs) across basolateral membranes of kidney, small intestine and liver epithelial cells, and across the plasma membrane of non-epithelial cells like skeletal myocytes. Its role for body AA homeostasis has now been investigated using newly generated TAT1 (Slc16a10) defective mice (tat1−/−). These mice grow and reproduce normally, show no gross phenotype and no obvious neurological defect. Histological analysis did not reveal abnormalities and there is no compensatory change in any tested AA transporter mRNA. TAT1 null mice, however, display increased plasma, muscle and kidney AAA concentration under both normal and high protein diet, although this concentration remains normal in the liver. A major aromatic aminoaciduria and a smaller urinary loss of all substrates additionally transported by l-type AA antiporter Lat2–4F2hc (Slc7a8) were revealed under a high protein diet. This suggests an epithelial transport defect as also shown by the accumulation of intravenously injected 123I-2-I-l-Phe in kidney and l-[3H]Phe in ex vivo everted gut sac enterocytes. Taken together, these data indicate that the uniporter TAT1 is required to equilibrate the concentration of AAAs across specific membranes. For instance, it enables hepatocytes to function as a sink that controls the extracellular AAAs concentration. Additionally, it facilitates the release of AAAs across the basolateral membrane of small intestine and proximal kidney tubule epithelial cells, thereby allowing the efflux of other neutral AAs presumably via Lat2–4F2hc.
Dietary and endogenous proteins are hydrolysed in the gastrointestinal lumen to tri-peptides, di-peptides and individual amino acids (AAs) that are taken up by small intestine enterocytes (Nassl et al. 2011). These cells hydrolyse the oligopeptides into single AAs and also further metabolize some of them. Finally, they release most AAs into the portal circulation, thereby strongly influencing the rate of AA appearance in plasma (Cynober, 2002; Wu, 2009). It is noteworthy that the amount of free AAs transported daily from the enterocytes into the circulation is much larger than the free AA pool of the plasma and extracellular space (∼100 g per day versus less than 10 g), such that their uptake into tissues is crucial for maintaining extracellular AA homeostasis (Cynober, 2002). In the cells of different organs, AAs may then serve as building blocks for the synthesis of structural and functional proteins, may be used for cellular metabolism or function as signalling molecules (Verrey et al. 2009; Wu, 2009). Therefore, AA transfer across plasma membranes via various cooperating AA transporters plays a crucial role for body AA homeostasis, and the defect of transporters leads to several diseases (Verrey et al. 2009; Broer & Palacin, 2011).
The best characterized basolateral AA transporters of the small intestine and proximal kidney tubule (re)absorbing epithelia are the abundant Lat2–4F2hc (Slc7a8) and y+Lat1–4F2hc (Slc7a7) that function as obligatory exchangers (antiporters). Thus, they do not mediate net AA transport, but are suggested to perform the directional transport of all their substrate AAs in exchange for AAs that can be recycled across the membrane by parallel transporters able to mediate a directional flux (Pfeiffer et al. 1999; Rossier et al. 1999; Meier et al. 2002; Fernandez et al. 2003; Verrey, 2003; Verrey et al. 2009). The role of Lat2–4F2hc has been recently investigated in vivo using a lat2 defective mouse (Braun et al. 2011). Its phenotype was mild, presenting an increase in several small neutral AAs in serum and a corresponding minor aminoaciduria. Based on these published data we estimate that the observed small urinary AA loss of lat2 null mice is not due to a decreased fractional excretion of AAs, and therefore surprisingly does not point to a substantial epithelial AA transport defect (Braun et al. 2011). Interestingly, aromatic AAs (AAAs) were not elevated in the serum of lat2 null mice, suggesting that another AA transporter plays a dominant role here, possibly the T-type AAA transporter TAT1 (Slc16a10), which was found slightly upregulated in the kidney of lat2 null animals. This transporter was molecularly identified and first characterized in 2001 by Endou and co-workers (Kim et al. 2001). In a later study, we have demonstrated using the Xenopus laevis oocyte expression system that TAT1 functions as a facilitated diffusion pathway that mediates the transport of AAAs l-Phe, l-Trp and l-Tyr with symmetric low apparent affinities, for instance with a K0.5 of approximately 30 mm for l-Phe influx and efflux (Ramadan et al. 2006). Interestingly, TAT1 protein was shown to co-localize in the kidney proximal tubule with the two exchangers mentioned above (Ramadan et al. 2007), and also to localize to the basolateral membrane of small intestine enterocytes and the sinusoidal membrane of perivenous hepatocytes (Ramadan et al. 2006). The analysis of tat1 mRNA expression by real-time polymerase chain reaction (PCR) revealed its presence in the epithelial tissues mentioned above, and also in muscles and brain (Ramadan et al. 2006). Finally, it was demonstrated that AAAs effluxing via TAT1 can be recycled into the cell by the exchanger Lat2–4F2hc and thereby drive the efflux of other intracellular neutral AAs that are substrates of Lat2–4F2hc (Ramadan et al. 2007). To investigate the role that TAT1 plays in whole-body AA homeostasis maintenance and in epithelial AA transport, we generated a TAT1 knockout (tat1−/−) mouse and present here its first characterization.
The tat1 knockout mouse model was produced by Ingenium Pharmaceuticals AG (Germany) using ENU (N-ethyl-N-nitrosurea) mutagenesis (Augustin et al. 2005; Keays et al. 2007). The nonsense mutation in the tat1 gene leads to a premature stop at position 88 (Y88*). The mice were backcrossed 10 times in a C57Bl/6J inbred strain (Charles River, Germany), which was the background of the parental female, whereas the mutagenized sperm was C3HeBFeJ. All animals were housed in standard conditions in normal light cycle and fed a standard diet prior to experiment. All procedures for mouse handling were according to the Swiss Animal Welfare laws and approved by the Kantonales Veterinäramt Zürich.
Immunofluorescence and real-time PCR
The anti-mTAT1 antibody used has been previously characterized (Ramadan et al. 2006), and tissues were processed as described elsewhere (Rossier et al. 1999). mRNA was extracted and quantified as described before (Ramadan et al. 2006), with the only difference that the reference gene used was HPRT (hypoxanthine guanine phosphoribosyl transferase).
Mice were put on a rotating drum with an accelerating (day 1, 6–60 r.p.m.) or fixed speed (day 2, average speed reached on day 1; Ugo Basile, model 47600, Italy; Sugiura et al. 2005). The time at which the animal drops off the drum was measured (maximal testing time: 300 s). Five trials were performed on each day. The average value from four different experimental days was calculated.
Different protein diets and metabolic cage experiments
Ten-week-old tat1−/− and wild-type (wt) littermate mice were fed sequentially with a normal protein diet (20% casein) followed by 8 days of high protein diet (40% casein). The modified standard diet AIN93G was maintained isocaloric by adjusting the starch content (Kliba-Nafg, Switzerland). Chow was put as pellet directly in the normal cages or reduced to powder for the metabolic cage experiment. Mice were weighed daily, and every third day put into metabolic cages (Tecniplast, Buguggiate, Italy) from 08.30 to 16.30 h to adapt, and 24 h (08.30–08.30 h) at the end of each diet period. At the end of the 24 h, urine and faeces were collected, and food and water consumption recorded. Urinary pH was measured using a pH microelectrode (691 pH-meter, Metrohm). Urinary creatinine was measured by the Jaffe method (Seaton & Ali, 1984). Urinary and plasma urea were measured using the diacetyl monoxime method (Wybenga et al. 1971). Urinary electrolytes (Na+, K+, Ca2+, Mg2+, Cl−, SO42−) were measured by ion chromatography (Metrohm ion chromatograph, Switzerland). Blood was collected through a single tail tip cut into Na+-heparinized micro-haematocrit-tubes (Provet AG, Switzerland) and plasma collected after centrifugation at 6000 g at 4°C. Animals were anaesthetized with Isoflurane (Provet AG) and killed by decapitation. After death, organs were harvested, frozen in liquid nitrogen and stored at −80°C. For AA measurements, organs were lysed using MagNa Lyser Green Beads (Roche, Switzerland) in PBS supplemented with 1 μl ml−1 Protease Inhibitor Cocktail (Sigma, Switzerland), in a ratio of wet weight to PBS volume of 1:3. Supernatant was collected after two 15,000 g centrifugations for 15 min at 4°C.
The analysis was done by the Functional Genomics Center Zurich (FGCZ). Samples were deproteinized with 10% sulphosalicylic acid, and AA concentrations were determined using the MassTrak Amino Acid Analysis Solution (Waters, Milford, USA) according to the manufacturer's instructions. The tat1−/− plasma AA ratios represented in Fig. 3B were normalized to the wt ones that were measured within the same diet and that are directly depicted in Fig. 3A. The same procedure was used to obtain the normalized urinary values depicted in Fig. 5B.
Micro-SPECT/computed tomography (CT) imaging and biodistribution analysis
Imaging and biodistribution of the AAA analogue 123I-2-I-l-Phe was performed in wt and tat−/− mice. 123I-2-I-l-Phe was synthesized as described before (Bauwens et al. 2007). Animals injected with 123I-2-I-l-Phe were anaesthetized and imaged 30 min after intravenous injection with a micro-SPECT (e.cam 180; Siemens, Brussels, Belgium) and a micro-CT (Skyscan 1178; Skyscan, Belgium) system as described before (Lahoutte et al. 2002, 2003, 2004; Bauwens et al. 2007; Vanhove et al. 2011). Images were visualized with the AMIDE 0.9.1 software, where micro-CT is represented in grey scale and micro-SPECT in NIH colour scale (Loening & Gambhir, 2003). After imaging, animals were killed and dissected. All major organs and tissues were collected and counted in a gamma camera counter (Canberra, Belgium) and expressed as percentage of injected activity per gram of organ or tissue.
Everted gut sacs
Uptake on the first two-thirds of the proximal small intestine segments of radiolabelled l-Phe and d-Mannitol was performed as described elsewhere (Nassl et al. 2011). Shortly, everted gut sacs were incubated for 10 min at 37°C in bubbling (95% oxygen and 5% carbon dioxide) Krebs-Tris buffer (pH 7.4) containing 100 μm l-Phe, 0.5 μCi l-[3H]Phe/ml (Hartmann Analytic, Germany), 0.02 μCi 14C-d-mannitol/ml (ARC, USA). After brief washing, sacs were cut open and content activity counted (serosa). Sacs were further dried at 55°C O/N on cellulose (Sartorius AG, Germany) and weighed. The sacs (tissue) were lysed in Solvable (Perkin Elmer, Switzerland) for 6 h at 50°C, bleached with 200 μl of 30% H2O2, and the radioactivity was determined by liquid scintillation in 15 ml of Ultima Gold (Perkin Elmer). AA transport was expressed relative to the dry tissue weight.
Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, USA) and R 2.14 (R Foundation of Statistical Computing). Unless mentioned otherwise, between-group comparisons were performed by Student's unpaired t test or by repeated-measures one-way ANOVA, followed by Bonferroni post hoc test. Statistical significance was accepted at P < 0.05 or as indicated. Data are presented as means ± SEM.
A tat1 knockout mouse (tat1−/−) was produced by ENU mutagenesis (Ingenium Pharmaceuticals AG) in the context of the former European EUGINDAT project. The nonsense mutation (Y88*) was confirmed by DNA sequencing, and the mice were backcrossed 10 times into C57Bl/6J background. Absence of tat1 expression was confirmed using immunofluorescence and mRNA analysis. The TAT1 protein was indeed not detected in any of the knockout samples tested (Fig. 1B and D), and the tat1 mRNA levels were decreased in all tested tissues, but in white adipose tissue (see online Supplemental Table 1a and b, tat1), presumably due to nonsense mediated decay (Maquat, 1995).
Mild phenotype under normal conditions
tat1−/− pups grew normally and showed no visible phenotype when compared with their wt littermates (online Supplemental Fig. 1). Once adult, tat1−/- mice showed no body weight difference compared with wt (Table 1), they were fertile and gave birth to normal litters matching the expected Mendelian distribution (data not shown). AAAs transported by TAT1 such as l-Trp and l-Tyr are known to be precursors of serotonin, catecholamines and thyroid hormone. Thus, the absence of TAT1 transporter could potentially impact on neurotransmitter and thyroid hormone availability, and lead to neurological disorders. Although no gross behavioural change was observed, the motor activity and coordination skills of the mice were tested using a RotaRod test (Karl et al. 2003), which, however, showed no difference between tat1−/− and wt littermates (Fig. 2). In an attempt to exacerbate a potential phenotype, the same experiment was carried out after subjecting the mice to a low protein diet (7% casein) for 5 days, without revealing any difference between the two groups (data not shown). In order to visualize a potential abnormal behaviour of tat1−/− mice, the animals were video recorded in their normal cage prior and after fasting (data not shown), and their feeding and drinking behaviour recorded for 24 h in metabolic cages (Table 1; Supplemental Table 2). Again, no difference was observed between tat1−/− mice and their wt littermates, except for a slight increase in water intake and urinary volume that was larger than expected from the increased aminoaciduria (see below). A histological analysis of kidney, liver and intestinal segments on haematoxylin eosin-stained sections also did not reveal any abnormality (Supplemental Fig. 2). A possible upregulation of other AA transporters was then investigated as compensatory mechanisms for TAT1 absence, but no significant change was noticed at the level of any tested AA transporter mRNA in various different organs (Supplemental Table 1a and b) nor at the level of B0AT1, TMEM27 and Lat2 proteins tested in kidney (data not shown). Also the carbohydrate metabolism did not appear to be perturbed, as indicated by a normal oral glucose tolerance test (Supplemental Fig. 3).
|Males||Normal protein diet (20% casein)||High protein diet (40% casein)|
|pH||6.36*± 0.03||6.46 ±0.07||6.05 ± 0.06 c†||6.11 ± 0.02 d|
|Creatinine (mg per 24 h)||0.174 ± 0.036||0.510 ± 0.088||1.150 ± 0.299 c||1.898 ± 0.316 d|
|Creatinine (mg dl−1)||40.2 ± 2.6||32.1 ± 2.9||22.8 ± 5.9 c||17.8 ± 0.9|
|Urea (mg dl−1)/crea (mg dl−1)||166.7 ± 53.4||133.9 ± 23.4||332.1 ± 32.9 c||277.6 ± 29.5 d|
|Na+ (mm)/crea (mg dl−1)||8.58 ± 0.57||7.90 ± 0.49||9.45 ± 1.22||7.18 ± 0.98|
|K+ (mm)/crea (mg dl−1)||7.27 ± 0.26||6.38 ± 0.34||6.88 ± 0.71||5.38 ± 0.62|
|Ca2+ (mm)/crea (mg dl−1)||0.041 ± 0.001||0.048 ± 0.009||0.089 ± 0.008 c||0.078 ± 0.009|
|Mg2+ (mm)/crea (mg dl−1)||0.52 ±0.06||0.36 ± 0.05||0.70 ± 0.13||0.59 ± 0.10|
|Osmolality (mosmol (kg H2O) −1)||3148 ± 174||2260 ± 192||2660 ± 497||2072 ± 199|
|Urine volume (ml (g BW)−1)||0.046 ± 0.005||0.086 ± 0.009||0.112 ± 0.019 c||0.164 ± 0.013 d|
|Water intake (ml (g BW)−1)||0.131 ± 0.014||0.244 ± 0.028 a||0.272 ± 0.023 c||0.362 ± 0.021 d|
|Food intake (g (g BW)−1)||0.142 ± 0.013||0.165 ± 0.010||0.144 ± 0.009||0.153 ± 0.009|
|Faeces (g (g BW)−1)||0.021 ± 0.002||0.023 ± 0.001||0.020 ± 0.002||0.019 ± 0.002|
|Body weight (g)||28.1 ± 1.0||25.7 ± 0.3||27.6 ± 0.8||26.2 ± 0.6|
|Body weight (% change)||1.00 ± 0.00||1.00 ± 0.00||0.99 ± 0.01||1.02 ± 0.02|
Altered homeostasis of AAAs
To assess the general impact of TAT1 absence on AA homeostasis, we measured the plasma concentration of proteinogenic AAs. Surprisingly, the AAA plasma concentration of tat1−/− mice was 2, 3 and 7.5 times higher than in wt for l-Phe, l-Trp and l-Tyr, respectively (Fig. 3B). In contrast, many other AAs were significantly diminished in tat1−/- plasma (i.e. Gly, l-Ala, l-Met, l-Ser, l-Thr, l-Asn, l-Gln, l-Lys and l-Arg). In view of the mild general phenotype observed under normal protein diet (20%), the animals were challenged for 8 days with a high protein diet (chow containing 40% of casein). This treatment did not significantly affect their body weight and, besides the expected high urea and creatinine excretion and the lower urinary pH, only an increased fluid intake and urinary volume were observed that can be explained by the increased urea excretion (Table 1; Supplemental Table 2). Indeed, the urea concentration in the urine amounted to ∼1350 mmol l−1 under normal diet and ∼1600 mmol l−1 under high protein diet. tat1−/− mice displayed similar values as their wt littermates with a more pronounced effect on fluid intake. Upon a switch to high protein diet, the plasma AAs remained stable in wt animals, with the exception of the branched-chain AAs (BCAAs) that increased (Fig. 3A). In tat1−/− mice, the diet had a similar effect as in wt mice, and maintained the peculiar pattern observed under normal diet: an elevated concentration of AAAs and a low concentration of all other AAs, except the BCAAs, which followed the dietary effect observed in the wt (Fig. 3B).
To further investigate the cause of the AA imbalance, free cytosolic AAs were measured in organs that represent the major reservoirs and metabolic sites: kidney, liver and skeletal muscles. The cellular concentrations of five representative AAs are depicted in Fig. 4. The AAAs l-Tyr and l-Trp displayed values strictly parallel to plasma in kidney and skeletal muscle. In contrast, in liver AAAs remained at the same lower concentration in tat1−/− as in wt. The organ concentrations of all non-AAAs were similar in tat1−/− as in wt animals, as shown for l-Val and l-Leu (Fig. 4). One peculiarity is the high l-Phe values measured in kidney. This value might be related to the role of the kidney for the production of l-Tyr from l-Phe.
Altered epithelial AA transport
The analysis of 24 h urine collected in metabolic cages showed that the dietary switch did not affect the AA excretion in wt animals (Fig. 5A). tat1−/− mice presented an aromatic aminoaciduria under normal protein diet that paralleled the high plasma values (Fig. 5B). However, under high protein diet, l-Tyr was found to be 64 times more abundant in tat1−/− than in wt urine, and l-Trp and l-Phe, 95 and 9 times, respectively. Furthermore, many other neutral AAs were also present in higher amounts in tat1−/− urine (i.e. between two- and ninefold), including all other substrates of the Lat2–4F2hc broad selectivity neutral AA exchanger. This indicates that under normal protein diet tat1−/− mice had an almost normal or only slightly increased fractional excretion of all AAs. In contrast, the high protein diet provoked in tat1−/− mice a high urinary excretion of AAs corresponding to a major increase of their fractional excretion. This inability of the kidney to maintain a low fractional excretion was selective of AAs, as all other measured urinary parameters did not display any significant difference between tat1−/− and wt control mice (Table 1).
Because TAT1 is expressed in the basolateral but not in the apical membrane of kidney proximal tubule, we hypothesize that the observed aminoaciduria might derive from an impaired basolateral export rather than from a defective apical import into epithelial cells. To verify this hypothesis, we used the isotopes 123I-2-I-l-Phe and 125I-2-I-l-Phe. These iodinated AAs are used as markers for oncologic imaging outside the brain, as their accumulation reflects the increased AA transport activity of cancer cells (Jager et al. 2001; Lahoutte et al. 2003). Their biodistribution has already been assessed and their validity demonstrated (Lahoutte et al. 2001, 2003, 2004). When tested in the Xenopus laevis oocytes expression system, the compound (2-I-l-Phe) was shown to efficiently compete for l-Phe transport, whether mediated by TAT1, Lat4 (Slc43a2) or Lat2–4F2hc (Supplemental Fig. 5). Exploiting the micro-SPECT/CT technique, the 123I-2-I-l-Phe isotope was used for live imaging of its distribution 30 min after intravenous injection (Fig. 6). Indeed a higher accumulation of the compound was clearly detected in both kidneys of the tat1−/− mouse (Fig. 6B). This qualitative observation was verified by the quantification of the accumulated counts after death (n= 3; Fig. 6C).
Like the kidney proximal tubule, TAT1 is also expressed in the basolateral membrane of epithelial cells along the small intestine (Ramadan et al. 2006; Supplemental Table 1). Therefore, AA transport was measured in everted gut sacs. A significant accumulation of l-[3H]Phe was observed in the enterocytes after 10 min incubation at 37°C (Fig. 7). Also a tendency for decreased net transepithelial transport into the serosal compartment was observed. These data support the hypothesis that TAT1 absence reduces the transepithelial transport of AAAs by decreasing their basolateral efflux.
Although the lack of TAT1 does not prevent the normal development and fertility of mice, the study of the newly developed tat1−/− mouse revealed a number of important functions of this low-affinity AAA uniporter that impact on body AA homeostasis. For instance, the disruption of TAT1 is shown to prevent the liver in playing its central role for the metabolism of AAAs. It is indeed well known that the accumulation of AAs as response to high protein diet is counteracted by an increase in liver AA catabolism (Moundras et al. 1993). In particular, the liver is the major metabolic organ for the catabolism of AAAs (Schimassek & Gerok, 1965; Brosnan, 2003), and its failure causes an increase of AAAs in plasma (Fischer et al. 1976; Brosnan, 2003). This leads to a decrease of the BCAAs/AAAs ratio (Fischer ratio), and the consecutive increase of AAA uptake into the brain has been suggested to be a major cause of hepatic encephalopathy (James et al. 1979; Dejong et al. 2007). Here we show that plasma AAAs are stably elevated in tat1−/− mice regardless of the dietary load (Fig. 3). This increase is reflected in skeletal muscles, suggesting that TAT1 is not necessary for the AAA equilibration between plasma and this compartment (Fig. 4; Supplemental Table 1b). In contrast, in the liver of tat1−/− mice the intracellular AAA values are normal, indicating that the transport between the plasma that contains an elevated AAA concentration and this organ is uncoupled (Fig. 8). The present data document that tat1 mediates the equilibration of the extracellular AAA concentration with the hepatocytes, and suggests that the liver functions as a sink for the AAAs and thereby sets their concentration and controls their body homeostasis.
AAAs play important roles in the brain. Both increased and decreased levels are thought to impair brain function, as mentioned above for the increase in AAAs due to liver failure that contributes to hepatic encephalopathy. Dietary l-Trp restriction that was shown in mice to result in altered emotional response to stress and increased locomotor activity is one example in which a decreased level of AAAs leads to an alteration of brain functions (Uchida et al. 2005). However, a more recent study found no correlation between l-Trp depletion, central serotonin reduction and affective behavioural changes (van Donkelaar et al. 2010). The lack of signs of hepatic encephalopathy or behavioural disorders in tat1−/− suggests that the AAA concentration within the brain is normal or at a level that has no gross functional consequences. This suggests that the blood–brain barrier function is intact, as expected based on our observation that tat1 is not expressed in mouse blood–brain barrier endothelial cells (Lyck et al. 2009).
The absence of behavioural and growth alterations also suggests that the lack of TAT1 does not have a major impact on the function of thyroid hormone, although this transporter was shown to facilitate the diffusion of both T3 and T4 (Friesema et al. 2008). Recent investigations from the laboratory of Heike Heuer indeed confirm that thyroid hormone metabolism is not altered in TAT1 null mice (personal communication).
The placenta is another cellular barrier that expresses TAT1 but for which this transporter appears to be dispensable in laboratory conditions (Meredith & Christian, 2008). Indeed, tat1−/− foetus develops normally and tat1−/− female mice are normally fertile. After birth, tat1−/− mice maintain the capacity to absorb AAs from nutritional sources. This indicates that intestinal AA absorption and in particular the basolateral efflux of (aromatic) AAs from enterocytes is possible also in the absence of TAT1. We therefore tested for the upregulation of some other transporters that could compensate for the lack of TAT1. However, none of the other basolateral neutral AA transporters was found to be upregulated at the mRNA level in intestine and kidney, which suggested that the residual AAA transport capacity and potential paracellular transport can compensate for tat1 absence under normal diet.
An important finding is the massive loss of AAAs and more discrete loss of all substrate AAs of the neutral exchanger Lat2–4F2hc in the urine of tat1−/− mice under high protein diet (Fig. 5). This aminoaciduria implies that the maximal transport capacity for these AAs was exceeded in kidney proximal tubule, and reveals the role of TAT1 for epithelial AA transport. Furthermore, it is suggested that this (aromatic) AA loss explains the fact that the tat1−/− mouse plasma AA concentration does not additionally change much under high protein diet. In our assay the urine was collected over 24 h, whereas the blood was collected once (i.e. 3 h after the switch to the inactive light phase). It is thus conceivable that under normal protein diet the AA transport rate is near the maximal transport capacity of the proximal tubule, already within the so-called splay, where some nephrons do not have the capacity of reabsorbing all substrates. Because the plasma AA levels depend also on nutritional intake and are higher during the absorptive phase, under high protein diet a transient increase in blood AAs might cause the AA spillover. The urinary AA pattern (very high TAT1 substrates, increased Lat2–4F2hc substrates) is in line with the suggested functional cooperation of the uniporter TAT1 with the exchanger Lat2–4F2hc for the net efflux of neutral AAs, as previously shown in the Xenopus laevis expression system (Ramadan et al. 2007). Interestingly, the loss of l-Phe in the urine was lower than that of l-Tyr and l-Trp. We hypothesize that this is due to the ability of another basolateral uniporter to transport l-Phe. Indeed, we have shown that Lat4 (Slc43a2) is also localized in the basolateral membrane of proximal kidney tubule cells and of small intestine enterocytes (Bodoy et al. 2005; L. Mariotta, A. Guetg & F. Verrey, unpublished data). This transporter was first described by Bodoy et al. in 2005 and shown to mediate the facilitated diffusion of BCAAs, l-Met and l-Phe and, to a lesser extent, l-Pro, l-Tyr and l-Trp. The presence of this other uniporter for essential AAs and its selectivity might explain the differential urinary AAA pattern observed in tat1−/− mice (ninefold more l-Phe versus 64- and 95-fold more l-Tyr and l-Trp, respectively). Furthermore, Lat4 could to a large extent compensate for the absence of TAT1 in kidney and intestine, and thus explain the mild phenotype of tat1−/− mice. The lack of Lat4 expression in the liver does on the other hand explain the fact that in the absence of tat1 expression, the liver cannot function as a sink for AAAs (Bodoy et al. 2005).
To verify that AAAs are efficiently imported luminally into transporting epithelial cells of tat1−/− mice, where they accumulate due to their inefficient basolateral export and consequently inhibit the apical transport, in vivo micro-SPECT/CT and ex vivo everted gut sac experiments were performed. The results confirmed the accumulation of tracers inside the epithelial cells (Figs 6 and 7). However, the everted gut sacs experiments did not allow us to detect a significant difference in the net transcellular flux of l-Phe (Fig. 7: serosa). This was due to a substantial residual permeability of the small intestine epithelium of tat1−/− mice for AAAs that might explain the normal growth of tat1−/− mice. This residual permeability is presumably due to a large extent to the contribution of the other uniporter Lat4, as mentioned above. We hypothesize, however, that a paracellular leak might also contribute to this permeability, as previously suggested for glucose and phosphate (Danisi & Murer, 1991; Pappenheimer, 1993; Ballard et al. 1995).
A defect in tat1 has been predicted to be the cause of the blue diaper syndrome (Kim et al. 2001; Broer, 2008; Broer & Palacin, 2011). This syndrome was initially described by Drummond and co-workers in 1964, and appears to be caused by an excess of unabsorbed l-Trp in the intestinal tract (Drummond et al. 1964). We did not observe any symptom reminiscent of this syndrome in tat1−/− mice. Furthermore, the amount of l-Trp found in the distal part of the small intestine was similar to wt (Supplemental Fig. 6) and much less than observed in Hartnup disorder (D. Singer & F. Verrey, unpublished results).
In summary, the analysis of tat1−/− mice confirmed that a complex machinery of AA transporters functionally cooperates for the absorption and distribution of dietary AAs (Fig. 8). Our data further indicate that TAT1 exerts a major homeostatic function by equilibrating the concentration of AAAs between plasma and hepatocytes, where the AAAs are in turn catabolized. The functional impact of TAT1 absence becomes more evident under high protein diet, when the transport capacity of the kidney is exceeded such that a massive aromatic and also a neutral aminoaciduria appear that contributes in maintaining AA plasma homeostasis. We show that the aminoaciduria originates from an accumulation of AAs in the epithelial cells and we postulate that another basolateral uniporter, Lat4 (Slc43a2), compensates to a substantial extent for the lack of TAT1, in particular for driving the export function of the exchangers Lat2–4F2hc and y+Lat1–4F2hc in small intestine and kidney proximal tubule.
L.M., S.M.R.C., T.L. and F.V.: conception and design of the experiment. L.M., D.S., A.G., B.H., S.M.R.C. and F.V.: collection, analysis and interpretation of data. L.M. and F.V.: drafting and revising the article. All authors approved the final version.
The authors thank David Wolfer for his help in using the RotaRod, Hannelore Daniel for helpful discussions, and the Functional Genomics Center Zurich (FGCZ) for the amino acid analysis. This work was supported by the Swiss National Science Foundation grant 31-130471 to F.V.